Clinical trial
Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral…
NCT00370565 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00370565 |
|---|---|
| Title | Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy. |
| Official title | Efficacy And Safety Of Exubera (Inhaled Insulin) Therapy In Subjects With Type 2 Diabetes Mellitus Not Well Controlled With Combination Oral Agents: A Three-Month, Outpatient, Parallel Comparative Trial. |
| Lead sponsor | Pfizer, Industry |
| Collaborators | Sanofi Industry Nektar Therapeutics |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Inhaled Human Insulin |
| Enrollment | 345 |
| Start date | Jun 1, 1999 |
| Completion | Sep 1, 2000 |
| First posted | Aug 31, 2006 |
| Last update posted | Feb 13, 2007 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: